The Quest for the
Added to the ObGyn's responsibility for managing patients sexual health is the emerging concept of sexual enhancement surgery, which includes…
A Complete Guide to Understanding Orgasms.
A Special Book Excerpt! The Science of Orgasm, by Drs. Barry R. Komisaruk, Carlos Beyer-Flores & Beverly Whipple, author of The…
Read More.. about mens sexual health.
from the American Urological Association annual 2011-2012 meeting.
HOSPITAL DISCHARGES INDICATE MORE MEN MAY REQUIRE SURGERY FOR BPH Rising numbers of acute renal failure cases in BPH patients… Read More..
A Shock to Men and a Major ‘Right On’ for Women. Want to have a happier relationship? Here’s a tip for straight men in the middle of long term relationships: Take… Read More..
Added to the ObGyn's responsibility for managing patients sexual health is the emerging concept of sexual enhancement surgery, which includes… Read More....
Will you join us in telling the FDA that it is time to even the score and give women the options they deserve for the treatment of sexual dysfunction? Sign the petition today and become an advocate for women’s sexual health equity.
It’s called the “little pink pill,” a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it’s approved, it would become the first drug of its kind on the market.
The drug Flibanserin is locked in a heated battle for approval from the U.S. Food and Drug Administration, raising controversial questions about why there are so many sexual enhancement drugs available for men and zero for women. To read the whole article CLICK HERE
We recently learned that the manufacturer that now owns Flibanserin has filed an appeal of a recent FDA denial, saying that other drugs have been approved with less data and more extreme side effects. And that’s reignited discussion about whether pharmaceutical products targeting women’s sexual disorders are evaluated on a level—or relevant—playing field.
Flibanserin, Librido, and Lybridos (and a small handful of others) are all drugs designed to play a part in awakening libido for women. They counter hypoactive sexual desire disorder (HSDD), in physicians’ terminology (the rest of us call it “not tonight—or tomorrow night, either” syndrome). There are, for context, a couple of dozen FDA-approved drugs for the comparable problem among men, including Viagra, the blue pill.
I don’t have the insider information I’d need to assert a double standard, although people I know and respect—like my colleague Sheryl Kingsberg, PhD,—suggest there is one. Women’s health psychologist at University Hospitals MacDonald Women’s Hospital, Sheryl said, “There’s a double standard of approving drugs with a high risk for men versus a minimal risk for women.” The side effects for Flibanserin, for example, were reported as dizziness and nausea; Sheryl compares those to side effects of penile pain, penile hematoma, and penile fracture—all from a drug that was approved.
That does sound like some extra protectiveness of women. Given my focus on sexual health for women, I run into a lot of cultural expectations and hesitations; we Americans are still just a bit prudish when it comes to, especially, older women having sex. That’s in spite of what I see in my practice every day: Women themselves want to live whole lives, which means being physically active, emotionally engaged, and sexually active within their relationships.
I recognize that sexuality for women is complex, and there won’t be a “magic bullet.” For women, arousal and desire is a mix of emotional intimacy, biological responses, and psychological responses; a drug won’t address all of the components. But because I’m often working with patients to untangle interlocking causes of problems with sex, I’m eager for as many tools as possible, including pharmaceuticals.
As a physician, I also see the need to evaluate trade-offs and risks. I’ve talked before about the pros and cons of hormone therapy. For some women, living longer doesn’t really count if they’re not able to be active—including being actively sexual. “Pink Viagra” drugs may well require the same kind of close collaboration between women and their doctors to evaluate risks and benefits. Again, Sheryl: “Give women a chance to decide for themselves, within reason. There is no drug out there that has no risk.” In the case of Flibanserin, only 8 percent of testers said the side effects were bad enough to make them want to drop the drug.
These decisions by the FDA are also important because pharmaceutical research is done by businesses, businesses that can decide that one problem or another is too expensive or too complicated to take on. Sheryl sees this, too, saying, “My worry is that research in this area will dry up and will leave many women without a pharmacological option.”
One way to make your voice heard about the importance of continued research is by signing the International Society for the Study of Women’s Sexual Health (ISSWSH) WISH petition.(The petition link is on the home page of Vibrance sites, eg www.hisandherhealth.com( Our sexual health is integral to our overall health, and we need more investigation and even-handed, common-sense consideration of therapies for women.